Form 4: Lexicon Pharmaceuticals Director Amouyal Reports Stock Transactions
SEC Form 4 Filing
Director Philippe Amouyal reports the vesting of restricted stock units and subsequent ownership of Lexicon Pharmaceuticals common stock.
Summary
- On April 28, 2024, Philippe Amouyal, a director of Lexicon Pharmaceuticals, reported a transaction involving restricted stock units.
- 8,032 restricted stock units vested, converting into 8,032 shares of common stock.
- The transaction was executed at a price of $0.
- Following the transaction, Amouyal directly owns 248,364 shares of Lexicon Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential shifts in ownership and sentiment.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the director's holdings.
- The vesting of restricted stock units aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/28/2024 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 04/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.